Madrigal Pharmaceuticals, Inc. (MDGL)
Market Cap | 5.79B |
Revenue (ttm) | n/a |
Net Income (ttm) | -444.28M |
Shares Out | 21.31M |
EPS (ttm) | -23.13 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 173,397 |
Open | 279.41 |
Previous Close | 279.31 |
Day's Range | 271.44 - 282.54 |
52-Week Range | 119.76 - 299.98 |
Beta | -0.41 |
Analysts | Buy |
Price Target | 348.17 (+28.16%) |
Earnings Date | Aug 6, 2024 |
About MDGL
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for MDGL stock is "Buy." The 12-month stock price forecast is $348.17, which is an increase of 28.16% from the latest price.
News
Madrigal Pharma CEO talks competition in the GLP-1 space and new drug rollouts
Bill Sibold, Madrigal Pharma CEO, joins 'Fast Money' to talk GLP-1 drug competition, its liver disease treatment, its Mash drug rollout and more.
![](https://cdn.snapi.dev/images/v1/x/s/press17-2465846.jpg)
Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress
CONSHOHOCKEN, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis...
![](https://cdn.snapi.dev/images/v1/w/g/press20-2414201.jpg)
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
CONSHOHOCKEN, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis ...
![](https://cdn.snapi.dev/images/v1/m/h/press3-2389230.jpg)
Madrigal Statement on the Passing of Dr. Stephen Harrison
CONSHOHOCKEN, Pa., April 24, 2024 (GLOBE NEWSWIRE) -- The Madrigal team is shocked and saddened to learn of the passing of Dr. Stephen Harrison.
![](https://cdn.snapi.dev/images/v1/a/q/press4-2374525.jpg)
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., April 16, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), tod...
![](https://cdn.snapi.dev/images/v1/u/x/press3-2330134.jpg)
Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering
CONSHOHOCKEN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatit...
![](https://cdn.snapi.dev/images/v1/1/k/press17-2329625.jpg)
Madrigal Pharmaceuticals Announces Proposed Public Offering
CONSHOHOCKEN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatit...
![](https://cdn.snapi.dev/images/v1/a/n/rmfvihsgmvmn3pidlvt7zn6die-2326199.jpg)
Madrigal Pharma surges on FDA nod to first drug for fatty liver disease NASH
Shares of Madrigal Pharmaceuticals jumped about 30% on Friday after its oral drug became the first treatment to win the health regulator's nod for a fatty liver disease known as non-alcoholic steatohe...
![](https://cdn.snapi.dev/images/v1/i/o/107387832-1710452490047-gettyi-2325603.jpeg)
FDA approves Madrigal Pharmaceuticals drug as first treatment for common NASH liver disease
The FDA's decision means Madrigal has succeeded in a disease area that several larger companies have failed — or are still trying to break into.
![](https://cdn.snapi.dev/images/v1/7/i/im-722644size1777777777777778w-2325461.jpg)
Madrigal Pharmaceuticals gets first FDA approval for drug targeting liver disease MASH
Madrigal Pharmaceuticals Inc. on Thursday received the first Food and Drug Administration approval for a drug designed to treat a severe liver disease known as MASH.
![](https://cdn.snapi.dev/images/v1/n/o/press11-2325319.jpg)
Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis
CONSHOHOCKEN, Pa., March 14, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatiti...
![](https://cdn.snapi.dev/images/v1/a/k/akzg637gafjt7dixtn3yibvuja-2325377.jpg)
Madrigal's drug wins first US approval for fatty liver disease NASH as rivals circle
Madrigal Pharmaceuticals' drug became the first to win regulatory approval to treat a serious type of fatty liver disease formerly known as non-alcoholic steatohepatitis (NASH) as the race to tap a mu...
![](https://cdn.snapi.dev/images/v1/w/a/wa2tte4spjmnxczgeamaq273mu-2325333.jpg)
US FDA approves first drug for fatty liver disease NASH
The U.S. FDA has approved Madrigal Pharmaceuticals' drug for a fatty liver disease known as non-alcoholic steatohepatitis (NASH), the first treatment to get the nod for the condition and opening up a ...
![](https://cdn.snapi.dev/images/v1/r/h/press9-2298020.jpg)
Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer
CONSHOHOCKEN, Pa., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatit...
![](https://cdn.snapi.dev/images/v1/a/j/press11-2298022.jpg)
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
CONSHOHOCKEN, Pa., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatit...
![](https://cdn.snapi.dev/images/v1/d/a/press1-2248532.jpg)
Madrigal Pharmaceuticals Announces Additions to Its Leadership Team
CONSHOHOCKEN, Pa., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatit...
![](https://cdn.snapi.dev/images/v1/y/v/press10-2216209.jpg)
Madrigal Pharmaceuticals Presents Five Health Economics Outcomes Research Abstracts at the NASH-TAG Annual Conference
CONSHOHOCKEN, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatit...
![](https://cdn.snapi.dev/images/v1/d/1/conf14-2215520.jpg)
Madrigal Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
CONSHOHOCKEN, Pa., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepati...
![](https://cdn.snapi.dev/images/v1/h/d/press6-2166924.jpg)
Madrigal Pharmaceuticals Appoints Ronald Filippo as Chief Information Officer
CONSHOHOCKEN, Pa., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatit...
![](https://cdn.snapi.dev/images/v1/b/5/press12-2151996.jpg)
Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer
CONSHOHOCKEN, Pa., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatit...
![](https://cdn.snapi.dev/images/v1/i/2/press4-2141310.jpg)
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Third Quarter 2023 Financial Results
CONSHOHOCKEN, Pa., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatit...
![](https://cdn.snapi.dev/images/v1/h/p/press19-2083087.jpg)
Madrigal Pharmaceuticals Announces Pricing of $500 Million Public Offering
CONSHOHOCKEN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepat...
![](https://cdn.snapi.dev/images/v1/e/9/press3-2061563.jpg)
Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver Fibrosis
CONSHOHOCKEN, Pa., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepati...
![](https://cdn.snapi.dev/images/v1/k/s/biotech17-2057418.jpg)
Madrigal Pharmaceuticals shares fall after new CEO named
Shares of Madrigal Pharmaceuticals Inc. MDGL, +2.91% fell more than 7% premarket on Monday after the company appointed Bill Sibold, a former Sanofi SNY, +1.06% executive, as its new CEO. Sibold succee...